GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » Gross Profit

Renalytix (Renalytix) Gross Profit : $-0.01 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Renalytix Gross Profit?

Renalytix's gross profit for the three months ended in Mar. 2024 was $-0.07 Mil. Renalytix's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.01 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Renalytix's gross profit for the three months ended in Mar. 2024 was $-0.07 Mil. Renalytix's Revenue for the three months ended in Mar. 2024 was $0.54 Mil. Therefore, Renalytix's Gross Margin % for the quarter that ended in Mar. 2024 was -12.34%.

Renalytix had a gross margin of -12.34% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 6 years, the highest Gross Margin % of Renalytix was 46.10%. The lowest was -0.40%. And the median was 29.44%.


Renalytix Gross Profit Historical Data

The historical data trend for Renalytix's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Gross Profit Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Profit
Get a 7-Day Free Trial - - 0.69 0.87 0.72

Renalytix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 -0.16 -0.04 0.26 -0.07

Competitive Comparison of Renalytix's Gross Profit

For the Health Information Services subindustry, Renalytix's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renalytix's Gross Profit Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Gross Profit distribution charts can be found below:

* The bar in red indicates where Renalytix's Gross Profit falls into.



Renalytix Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Renalytix's Gross Profit for the fiscal year that ended in Jun. 2023 is calculated as

Gross Profit (A: Jun. 2023 )=Revenue - Cost of Goods Sold
=3.403 - 2.683
=0.72

Renalytix's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0.535 - 0.601
=-0.07

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Renalytix's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=-0.07 / 0.535
=-12.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Renalytix  (NAS:RNLX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Renalytix had a gross margin of -12.34% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Renalytix Gross Profit Related Terms

Thank you for viewing the detailed overview of Renalytix's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Renalytix (Renalytix) Business Description

Address
5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Executives
Howard Jr Doran officer: Chief Business Officer C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie director 85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain officer: President NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc. 10 percent owner 150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai 10 percent owner 1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills director, 10 percent owner C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling officer: Chief Financial Officer C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc. 10 percent owner ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount 10 percent owner ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming director, officer: Chief Technical Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium director C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough director, officer: Chief Executive Officer C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE

Renalytix (Renalytix) Headlines

From GuruFocus

Renalytix to Present at Stifel Healthcare Conference

By Value_Insider Value_Insider 11-03-2022

Renalytix announces a c.$20.3 million private placement

By Stock market mentor Stock market mentor 02-08-2023